Literature DB >> 33190524

Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis.

Sara Saberi1, Nuno Cardim2, Mohamad Yamani3, Jeanette Schulz-Menger4, Wanying Li5, Victoria Florea5, Amy J Sehnert5, Raymond Y Kwong6, Michael Jerosch-Herold6, Ahmad Masri7, Anjali Owens8, Neal K Lakdawala9, Christopher M Kramer10, Mark Sherrid11, Tim Seidler12, Andrew Wang13, Farbod Sedaghat-Hamedani14, Benjamin Meder14, Ofer Havakuk15, Daniel Jacoby16.   

Abstract

Entities:  

Keywords:  antagonists & inhibitors; cardiac myosins; cardiomyopathy, hypertrophic; drug therapy; magnetic resonance imaging; physiopathology

Mesh：

Substances：

Year:  2020        PMID： 33190524     DOI： 10.1161/CIRCULATIONAHA.120.052359

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  21 in total

Review 1.  Arrhythmias as Presentation of Genetic Cardiomyopathy.

Authors:  J Lukas Laws; Megan C Lancaster; M Ben Shoemaker; William G Stevenson; Rebecca R Hung; Quinn Wells; D Marshall Brinkley; Sean Hughes; Katherine Anderson; Dan Roden; Lynne W Stevenson
Journal:  Circ Res       Date:  2022-05-26       Impact factor: 23.213

Review 2.  Targeting the sarcomere in inherited cardiomyopathies.

Authors:  Sarah J Lehman; Claudia Crocini; Leslie A Leinwand
Journal:  Nat Rev Cardiol       Date:  2022-03-18       Impact factor: 49.421

Review 3.  Contemporary Diagnosis and Management of Hypertrophic Cardiomyopathy: The Role of Echocardiography and Multimodality Imaging.

Authors:  Takeshi Kitai; Andrew Xanthopoulos; Shoko Nakagawa; Natsuko Ishii; Masashi Amano; Filippos Triposkiadis; Chisato Izumi
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-25

4.  Future Role of New Negative Inotropic Agents in the Era of Established Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy.

Authors:  Barry J Maron; Martin S Maron; Mark V Sherrid; Ethan J Rowin
Journal:  J Am Heart Assoc       Date:  2022-05-03       Impact factor: 6.106

5.  Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter.

Authors:  Ahmad Masri; Iacopo Olivotto
Journal:  J Am Heart Assoc       Date:  2022-05-03       Impact factor: 6.106

6.  Percutaneous Intramyocardial Septal Radiofrequency Ablation in Patients With Drug-Refractory Hypertrophic Obstructive Cardiomyopathy.

Authors:  Mengyao Zhou; Shengjun Ta; Rebecca T Hahn; David H Hsi; Martin B Leon; Rui Hu; Jun Zhang; Lei Zuo; Jing Li; Jing Wang; Bo Wang; Xiaoli Zhu; Jiani Liu; Yupeng Han; Xiaojuan Li; Bo Xu; Lei Zhang; Lihong Hou; Chao Han; Jincheng Liu; Liwen Liu
Journal:  JAMA Cardiol       Date:  2022-05-01       Impact factor: 30.154

7.  Two Classes of Myosin Inhibitors, Para-nitroblebbistatin and Mavacamten, Stabilize β-Cardiac Myosin in Different Structural and Functional States.

Authors:  Sampath K Gollapudi; Weikang Ma; Srinivas Chakravarthy; Ariana C Combs; Na Sa; Stephen Langer; Thomas C Irving; Suman Nag
Journal:  J Mol Biol       Date:  2021-10-08       Impact factor: 6.151

Review 8.  Pushing the Limits of Medical Management in HCM: A Review of Current Pharmacological Therapy Options.

Authors:  Cristian Stătescu; Ștefana Enachi; Carina Ureche; Laura Țăpoi; Larisa Anghel; Delia Șalaru; Carmen Pleșoianu; Mădălina Bostan; Dragoș Marcu; Mircea Ovanez Balasanian; Radu Andy Sascău
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

9.  Characteristics of left atrial remodeling in patients with atrial fibrillation and hypertrophic cardiomyopathy in comparison to patients without hypertrophy.

Authors:  Sotirios Nedios; Borislav Dinov; Timm Seewöster; Frank Lindemann; Sergio Richter; Arash Arya; Nikolaos Dagres; Daniela Husser; Andreas Bollmann; Gerhard Hindricks; Andreas Müssigbrodt
Journal:  Sci Rep       Date:  2021-06-14       Impact factor: 4.379

10.  Loss of crossbridge inhibition drives pathological cardiac hypertrophy in patients harboring the TPM1 E192K mutation.

Authors:  Lorenzo R Sewanan; Jinkyu Park; Michael J Rynkiewicz; Alice W Racca; Nikolaos Papoutsidakis; Jonas Schwan; Daniel L Jacoby; Jeffrey R Moore; William Lehman; Yibing Qyang; Stuart G Campbell
Journal:  J Gen Physiol       Date:  2021-07-28       Impact factor: 4.086
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.